Regeneron Pharmaceuticals CEO Leonard Schleifer said the U.S. Constitution's patent protection clause has fostered a long tradition of American innovation [1].
This perspective highlights the intersection of legal frameworks and scientific progress. By linking constitutional law to biotech breakthroughs, Schleifer said that intellectual property protections are essential for the high-risk, long-term investments required to develop new medicines.
During an interview on CNBC's "Squawk Box" broadcast on April 24, 2026, Schleifer discussed the role of the 250-year-old patent protection clause [1]. He said this specific legal foundation has enabled the broader biotech sector to pursue complex research and development goals [1, 2].
Schleifer said that these protections provide the security necessary for companies to invest heavily in the discovery of new therapies [2]. According to Schleifer, this constitutional mandate has laid the groundwork for the modern scientific achievements that characterize the current pharmaceutical landscape [1, 2].
The CEO's comments emphasize the relationship between the U.S. legal system and the ability of private companies to sustain research cycles. The patent system is designed to grant inventors temporary exclusivity in exchange for public disclosure of their findings, a mechanism Schleifer said credits for supporting Regeneron's specific mission [1, 2].
This discussion comes as the biotech industry continues to navigate the balance between rewarding innovation and ensuring patient access to affordable care. Schleifer's focus on the constitutional origin of these rights suggests that the current system of intellectual property is not merely a regulatory preference but a fundamental pillar of the American economy [1].
“The U.S. Constitution's patent protection clause has fostered a long tradition of American innovation.”
The emphasis on the constitutional basis of patents suggests a strategic defense of intellectual property rights amidst growing global debates over patent waivers and drug pricing. By anchoring the argument in the U.S. Constitution, the industry leadership frames patent protection as a fundamental right that ensures the continued viability of the biotech research model.
